Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2026 Oct 26;20(10):e0014834. doi: 10.1371/journal.pntd.0014834

Hepatitis E in suspected acute hepatitis cases in Brazil: A comparison with hepatitis A

Ketti Gleyzer de Oliveira 1,2, Mariana Pinheiro Alves Vasconcelos 3, Julia Teixeira Ton 3, Silvia Naomi de Oliveira Uehara 4, Roberta Sitnik 1, Denize Ornelas Pereira Salvador de Oliveira 1, Layze Oliveira Castberg Sousa 1, Ricardo Andreotti Siqueira 1, Peter James Robinson 1, Thaís Senna de Paula Domingues 1, Caroline Thomas Panico 1, César Augusto Inoue 1, Maria Cecília Araripe Sucupira 1, Maira Marranghello Maluf 1, Fernanda de Mello Malta 1, Deyvid Amgarten 1, Erick Dorlass 1, Pedro Sebe 1, Arlene S Pinto 5, Cirley M D O Lobato 6, Adalgisa Ferreira 7, Elodie Hyppolito 8, Raymundo Paraná 9, Maria Isabel Schinoni 9, Edmundo Pessoa de Almeida Lopes 10, Magali C Luiz 11, Raquel F L Garcia 12, Sabrina Sabino da Silva 13, Aline Satie Oba-Kuniyoshi 14, Dennis Armando Bertolini 15, Mário Reis Álvares-da-Silva 16, Raul Salinas Arrojo 16, Eduardo Emerim 17, Gabriela P Coral 18, Paulo R Acosta 19, Marcelle Lucena 20, Rosângela Rodrigues Teixeira 21, Mônica da Costa Guedes 22, Livia Melo Villar 23, Lia Lewis Ximenez 23, Clarice Gdalevici 24, Maria Cássia Jacintho Mendes-Correa 25, Michele Soares Gomes-Gouvea 2, Flair José Carrilho 2, Gerson Sobrinho Salvador de Oliveira 26, Paulo Roberto A Ferreira 27, Pablo Andres Munoz Torres 25, Glória Selegatto 25, Luciana Vilas Boas Casadio 25, Simone Tenore 28, Olavo Henrique Munhoz Leite 29, Fernanda Fernandes Souza 30, Tânia Reuter 31, Francisco Souto 32, Michele Nascimento-Sales 33, Maria Lucia Gomes Ferraz 27, Ana Catharina de Seixas Santos Nastri 25, Ana Paula Maciel Gurski 34, Andréa Salomão 32, Bruna Emanuelle Alvarenga Fanis 34, Cristina Pimenta 34, Elton Carlos de Almeida 34, Flávia Moreno Alves de Souza 34, Gerson Fernando Mendes Pereira 34, Mario Peribañez Gonzalez 34,35, Raymundo Soares de Azevedo 36, João Renato Rebello Pinho 1,2,37,*
Editor: Anabella Clara Fantilli38
PMCID: PMC13766607  PMID: 42932379

Abstract

Hepatitis E virus (HEV) is an underrecognized cause of acute viral hepatitis worldwide, with growing public health relevance, particularly in settings where routine diagnostic testing is limited. Hepatitis A virus (HAV) is another epidemiologically related hepatitis virus, but few studies have directly compared these infections in Brazil. This study aimed to (1) determine the frequency of acute hepatitis E (AHE) and evaluate the contribution of HEV infection to the burden of hepatitis among patients with suspected acute disease attended in public healthcare institutions in Brazil; (2) assess the prevalence of acquired immunity to HEV and HAV; and (3) compare demographic characteristics, risk factors, and clinical-laboratory findings associated with HEV and HAV infections. We enrolled 1,721 adults (≥18 years) with suspected acute hepatitis from 16 Brazilian states between October 2019 and May 2023. Serum samples were tested for anti-HEV IgG/IgM and anti-HAV IgG/IgM by immunoassay and for HEV and HAV RNA by RT-PCR. Demographic, behavioral, clinical, and laboratory data were collected using a standardized questionnaire. Group comparisons were performed using univariate analyses and logistic regression, with statistical significance set at p < 0.05. Anti-HEV IgG was detected in 89 individuals (5.2%), whereas anti-HAV IgG was detected in 1,352 (78.6%). Anti-HEV IgG seroprevalence was higher in the South, Southeast, and Central West regions and among heterosexuals, and it increased with age, reaching 13.0% among individuals aged ≥65 years. Seropositivity was associated with markers of previous exposure or immunity, including HAV, HBV, Leptospira, and Toxoplasma. A total of 124 acute hepatitis cases were identified: 16 (12.9%) AHE and 108 (87.1%) acute hepatitis A (AHA). Compared with AHA cases, AHE cases occurred in older individuals and were more frequent among women and heterosexual participants. All AHA cases occurred in urban areas, whereas AHE cases were observed in both urban and rural settings. AHA cases showed higher aminotransferase levels and more frequent jaundice than AHE cases. HEV accounts for a small but distinct proportion of suspected acute hepatitis cases in Brazil and shows epidemiological and clinical characteristics that differ from HAV. Incorporating HEV testing into routine diagnostic algorithms may improve etiological clarification and surveillance of acute hepatitis.

Author summary

We conducted a multicenter study of 1,721 adults with suspected acute hepatitis from five Brazilian regions. Anti-HEV IgG was detected in 5.2% of participants, with clear geographic and demographic variation, whereas anti-HAV IgG was much more frequent (78.6%). AHA was much more frequent than AHE: 87.1% vs. 12.9%. We also identified distinct epidemiological profiles: AHE affected older adults, was more frequent among women and heterosexual individuals, and occurred in both urban and rural settings. AHE cases had milder clinical and biochemical profiles than AHA cases, which showed higher aminotransferase levels and more frequent jaundice. These findings highlight an important gap in routine diagnostic testing for acute hepatitis in Brazil, because hepatitis E may be missed without targeted testing. Adding HEV testing to standard diagnostic panels could improve patient care and public health surveillance.

Introduction

HEV was first recognized after large outbreaks of enterically transmitted non-A, non-B hepatitis in Asia, including epidemics in India and Afghanistan, and the viral agent was subsequently visualized as virus-like particles in stool samples [1]. HEV belongs to the family Hepeviridae, which includes multiple genera and species with human and animal hosts; among these, Paslahepevirus balayani includes the main human HEV genotypes, whereas Rocahepevirus ratti includes rat HEV strains with zoonotic potential [2]. HEV is a small, positive-sense single-stranded RNA virus with a genome of approximately 7.2 kb. The genome contains three principal open reading frames: ORF1 encodes the nonstructural polyprotein required for viral replication, ORF2 encodes the capsid protein, and ORF3 encodes a small multifunctional protein involved in virion release and pathogenesis. Virions are non-enveloped in feces but circulate in blood as quasi-enveloped particles surrounded by a host-derived lipid membrane [2].

HEV is now recognized as a major cause of acute viral hepatitis worldwide. The World Health Organization estimates that HEV caused approximately 20 million HEV infections worldwide every year, and 44,000 deaths in 2015 [3].

HEV genotypes differ in host range, geographic distribution, and transmission routes. Genotypes 1 and 2 infect humans and are mainly transmitted through fecally contaminated water, causing large outbreaks in regions with limited sanitation. Genotypes 3 and 4 circulate in animal reservoirs, particularly domestic pigs and wild boars, and cause sporadic zoonotic infections associated with raw or undercooked pork, game meat, shellfish, and other contaminated foods; transfusion-associated transmission has also been reported. Genotypes 5 and 6 have been detected in wild boars, whereas genotypes 7 and 8 occur in dromedaries and Bactrian camels, respectively, with rare human infection linked to camel-derived products [4–8].

HAV is another enterically transmitted hepatotropic virus and remains an important cause of acute viral hepatitis worldwide. HAV is a non-enveloped, positive-sense single-stranded RNA virus of the genus Hepatovirus in the family Picornaviridae. Three genotypes (I–III), each divided into subtypes A and B, infect humans; genotype I is the most prevalent worldwide, with subgenotype IA reported most frequently. HAV is transmitted mainly by the fecal–oral route through contaminated food or water or close person-to-person contact, including oral–anal sexual exposure. Unlike hepatitis B and C viruses, HAV does not cause chronic infection, but disease severity increases with age, and fulminant hepatitis may occur rarely [9,10].

The epidemiology of HAV has changed in many middle-income countries, including Brazil, where improvements in sanitation and the introduction of childhood vaccination have reduced early-life exposure while increasing the proportion of susceptible adolescents and adults in some settings. Universal HAV vaccination was incorporated into the Brazilian National Immunization Program in 2014 as a single-dose schedule for young children; however, heterogeneous coverage and regional socioeconomic differences may contribute to ongoing susceptibility and periodic outbreaks among older age groups and specific risk populations [11,12].

Because HAV and HEV share enteric routes of transmission and may present with overlapping clinical manifestations, distinguishing between these infections requires specific laboratory testing. In clinical practice, however, HEV is frequently not included in routine diagnostic algorithms for acute hepatitis in Brazil, which may lead to underdiagnosis, and misclassification of cases initially attributed to other causes, including HAV or drug-induced liver injury [5].

HEV epidemiology is commonly described according to two broad patterns. In endemic regions, particularly parts of Asia and Africa (especially in the Middle East), it is associated with large waterborne outbreaks linked to limited sanitation and unsafe drinking water [6]. In non-endemic or industrialized settings, sporadic autochthonous infections are increasingly recognized, frequently associated with zoonotic transmission, and can progress to chronic hepatitis in immunosuppressed individuals [13,14].

Risk factors for HEV infection and severe disease include residence in areas with inadequate sanitation, exposure to contaminated water, consumption of raw or undercooked pork or game meat, occupational contact with pigs, transfusion or invasive procedures, pregnancy, pre-existing liver disease, and immunosuppression, particularly in the context of genotype 3 infection [15].

During AHE, viremia usually peaks during incubation and early symptomatic phases, and serum HEV RNA may become undetectable within a few weeks after symptom onset, creating a narrow diagnostic window for PCR in blood. Viral RNA may be shed in feces for longer periods. Although most infections are self-limited, HEV can cause severe outcomes in vulnerable groups, including pregnant women, individuals with chronic liver disease, and immunosuppressed patients. Chronic infection, extrahepatic manifestations, and acute-on-chronic liver failure have also been described, particularly in association with genotype 3 infection [15–19].

In Brazil, available studies indicate heterogeneous HEV circulation across regions and populations. Reported anti-HEV IgG seroprevalence varies widely, from low levels in some northern populations to substantially higher estimates in the South and Southeast [20,21]. HEV has also been detected in several animal hosts and food-related sources, including pigs, wild rodents, horses, bovine liver, and capybaras, with genotype 3 detected where sequencing has been performed [20–27].

Despite evidence of zoonotic circulation, HEV testing is still not routinely performed in most Brazilian healthcare services. As a result, HEV infection may remain undetected among patients with acute hepatitis of unknown etiology, especially in those cases initially classified as HAV infection, drug-induced liver injury, or other causes. In countries where HEV testing has been incorporated into diagnostic workups, a proportion of presumed drug-induced liver injury cases has been reclassified as AHE [28].

This study aimed to (1) determine the frequency of AHE and evaluate the contribution of HEV infection to the burden of hepatitis among patients with suspected acute disease attended in public healthcare institutions in Brazil; (2) assess the prevalence of acquired immunity to HEV and HAV; and (3) compare demographic characteristics, risk factors, and clinical-laboratory findings associated with HEV and HAV infections.

These data are particularly relevant because HEV remains underdiagnosed in Brazil, and few multicenter studies have specifically evaluated AHE among patients with suspected acute hepatitis. Better characterization of HEV prevalence, exposure patterns, and clinical presentation may support improved diagnostic strategies, strengthen surveillance, and guide public health policies for acute hepatitis beyond hepatitis A, B, and C.

Materials and methods

Ethical statement

The project was approved by the Comissão Nacional de Ética em Pesquisa (CONEP; National Research Ethics Commission), the ethics committee responsible for approving multicenter studies such as this one, under the Certificado de Apresentação de Apreciação Ética (CAAE; Certificate of Presentation for Ethical Consideration) No. 00952818.4.1001.0071. All participants provided written informed consent before enrollment. For illiterate participants, consent was documented by fingerprint on the informed consent form. When participants were bedridden or unable to sign, consent was obtained from a close relative. The study protocol was conducted in accordance with the ethical principles of the Declaration of Helsinki.

Study design and setting

Patients and samples.

This multicenter prospective observational study sequentially enrolled individuals aged ≥18 years who sought care for clinical signs or symptoms suggestive of acute liver disease between October 2019 and May 2023. Participants were recruited at 31 viral hepatitis referral services across 16 Brazilian states, representing the North, Northeast, South, Southeast, and Central West regions. A total of 1,721 samples were collected. All samples were validated according to the study protocol and had sufficient volume for testing HAV and HEV infection markers.

Participants were enrolled as part of the study “Study of the epidemiological and clinical characteristics of acute viral hepatitis in Brazilian healthcare services”, which has been previously described [29]. The protocol included biochemical tests, serological and molecular testing for hepatitis A, B, C, D, and E viruses and HIV, and additional laboratory investigations for arboviruses, herpesviruses, other viral infections, toxoplasmosis, leptospirosis, syphilis, and autoimmune hepatitis. Results concerning HAV have been published previously [30], whereas analyses of other etiologies are ongoing.

Eligibility criteria were defined as follows: (1) icteric symptomatic cases, defined as sudden onset of jaundice within six months before enrollment, with or without fever, malaise, nausea, vomiting, myalgia, acholic stools, or dark urine, and serum aminotransferase levels ≥1.5 times the upper limit of normal (ULN); (2) anicteric symptomatic non-jaundiced cases, defined as absence of jaundice with one or more symptoms suggestive of acute hepatitis and serum aminotransferase levels ≥1.5 times the ULN; and (3) anicteric asymptomatic cases, defined as absence of jaundice and symptoms but with a sudden increase in aminotransferase levels ≥1.5 times the ULN and/or a recognized close contact with a patient with confirmed viral hepatitis.

Blood samples collected by venipuncture were properly identified with sequential labels provided and identified with the patients’ full names and then centrifuged for serum or plasma separation. After collection, the samples were adequately processed, stored, and subsequently sent for analysis along with the completed documents to the Albert Einstein Clinical Pathology Laboratory in São Paulo, capital city of São Paulo State, Brazil.

A standardized questionnaire was used to collect demographic data, including sex at birth, gender identity, age, and geographic origin, as well as information on viral infections and individual risk factors.

Case definition of AHE.

AHE was defined using clinical and laboratory criteria informed by international and national recommendations. For this study, a case was classified as AHE when biochemical evidence of acute hepatitis, characterized by a recent elevation in serum aminotransferases, was accompanied by anti-HEV IgM reactivity and/or detectable HEV RNA by nucleic acid amplification testing. The international guidelines differ in the evidentiary weight assigned to these markers. EASL defines current acute HEV infection by detectable HEV RNA, with or without anti-HEV IgM, and does not classify isolated anti-HEV IgM positivity as current acute infection. In contrast, WHO surveillance guidance accepts anti-HEV IgM positivity in a patient with compatible acute hepatitis as laboratory confirmation, while noting that an additional marker, such as HEV RNA, increases diagnostic specificity. Thus, the operational case definition used in this study is consistent with the WHO surveillance approach but is broader than the EASL definition of current acute infection. Isolated anti-HEV IgG positivity was interpreted as evidence of previous exposure and was not used to define acute infection. Participants with anti-HEV IgG reactivity were analyzed separately to assess factors associated with previous HEV exposure [31,32].

Serology for HAV and HEV.

Qualitative detection of anti-HAV IgM and IgG antibodies and anti-HEV IgM and IgG antibodies was performed in human serum samples using commercial immunoassays. HAV serology was performed using ARCHITECT HAVAb-IgM and HAVAb-IgG assays based on chemiluminescent microparticle immunoassay technology (Abbott Diagnostics, Abbott Park, IL, USA). HEV serology was performed using the recomWell HEV IgM and IgG assays (Mikrogen Diagnostik, Neuried, Germany), a qualitative enzyme-linked immunosorbent assays based on recombinant antigens from HEV genotypes 1 and 3. All laboratory procedures and interpretation of results were performed according to the manufacturers’ instructions.

HAV and HEV RNA detection by reverse transcription–polymerase chain reaction (RT-PCR).

Viral RNA was extracted from all plasma samples before HAV and HEV RNA detection by real-time RT-PCR. Extraction was performed on the automated QIAsymphony platform using the QIAsymphony DSP Virus/Pathogen Mini Kit (Qiagen, Hilden, Germany), with input volumes of 350 µL for HAV testing and 650 µL for HEV testing, according to the manufacturer’s instructions. Extracted RNA was eluted in 60 µL, aliquoted, stored at −80°C, and thawed only once before amplification. HAV RNA was detected using the RealStar HAV RT-PCR Kit 1.0, and HEV RNA was detected using the RealStar HEV RT-PCR Kit 2.0 (Altona Diagnostics, Hamburg, Germany). Samples with cycle threshold (Ct) values ≤40 were considered positive.

Sequencing of HEV RNA.

HEV RNA-positive samples were subjected to molecular characterization by amplification and sequencing of partial fragments from two genomic regions using previously described primers: a 287-bp fragment of ORF1 [33] and a 348-bp fragment of ORF2 [34]. These fragments were amplified by nested PCR after reverse transcription. Reverse transcription and the first PCR round were performed using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Life Technologies, Foster City, CA, USA), and the second PCR round was performed using Platinum Taq DNA Polymerase (Life Technologies). Second-round PCR products were purified using the ExoSAP-IT PCR Clean-up Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), using the same primers as those used for nested PCR targeting the ORF1 and ORF2 regions. Dye-labeled products were analyzed on a 3500 Genetic Analyzer (Applied Biosystems). Sequence quality was assessed using Phred-Phrap, and consensus sequences were generated using CAP3 software.

Statistical analysis

Statistical analyses were performed to compare demographic, behavioral, clinical, and laboratory variables across predefined groups. Two comparisons were evaluated: (1) patients with AHA versus patients with AHE, with acute infection defined by virus-specific IgM reactivity and/or viral RNA detection by RT-PCR; and (2) participants with evidence of previous HEV exposure, defined as anti-HEV IgG reactive, versus participants without evidence of previous HEV exposure, defined as anti-HEV IgG non-reactive.

Continuous variables were compared using Student’s t-test, and categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Statistical significance was set at p < 0.05. Variables with p < 0.05 in bivariate analyses were included as candidate predictors in backward stepwise logistic regression models for the two predefined outcomes: AHA versus AHE and anti-HEV IgG reactive versus non-reactive status. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were reported. Analyses were performed using RStudio statistical software (http://www.rstudio.com).

The dataset supporting the findings of this study has been deposited in the Open Science Framework (OSF) repository (https://osf.io/7gjsc).

Results

AHA and AHE cases

Among the 1,721 samples analyzed, 108 (6.3%) were classified as AHA: 99 were anti-HAV IgM reactive, of which 96 were also HAV RNA positive and three were HAV RNA negative, and nine were HAV RNA positive despite non-reactive anti-HAV IgM. Sixteen samples (0.93%) were classified as AHE; all were anti-HEV IgM reactive, and only one had detectable HEV RNA by RT-PCR. No simultaneous anti-HAV IgM and anti-HEV IgM reactivity was observed among the acute hepatitis cases. AHA was much more frequent than AHE, accounting for 87.1% of cases compared with 12.9% for AHE. Just the case with detectable HEV RNA was anti-CMV IgM positive. No case had detectable EBV VCA IgM. The median time from symptom onset to sampling was 12.5 days (mean: 15.75 days; IQR: 7.5-18.5 days; range: 0–47 days).

Among the 16 patients with AHE, the most frequently reported symptom was nausea, reported by 12 participants (75.0%). Anorexia and dark urine were each reported by nine participants (56.3%), while fever, jaundice, and vomiting were each reported by seven participants (43.8%). Acholic stools were reported by five participants (31.3%), hepatomegaly by four participants (25.0%), and splenomegaly and rash by two participants each (12.5%). These cases were added between 0–37 days after symptom onset. Only symptomatic patients were diagnosed as AHE.

Demographic and laboratory analyses revealed significant differences between the acute hepatitis groups. The mean age was higher among patients with AHE than among those with AHA (49.4 versus 34.9 years; p = 0.004). Mean ALT and AST levels were significantly higher in the AHA group (ALT: 1,150 U/L; AST: 599 U/L) than in the AHE group (ALT: 233 U/L; AST: 113 U/L; p < 0.001). The ALT/AST ratio and total and direct bilirubin levels were also higher in the AHA group (p = 0.034 and p = 0.036, respectively).

Demographic, clinical, and behavioral characteristics of patients with AHA and AHE are shown in Table 1; only statistically significant associations are presented, whereas non-significant results are provided in S1 Table. AHA was more frequent among males, participants from the Southeast region, individuals living in urban areas, bisexual or homosexual participants, cis men, symptomatic jaundiced cases, men who have sex with men (MSM), and individuals with non-reactive anti-Toxoplasma gondii IgG. In contrast, AHE was more frequent among females, participants from the South region, individuals living in rural areas, heterosexual participants, cis women, symptomatic non-jaundiced cases, participants with previous surgery, non-MSM, and individuals with reactive anti-Toxoplasma gondii IgG.

Table 1. Demographic, clinical, and behavioral characteristics of patients with acute hepatitis A (AHA) and acute hepatitis E (AHE).

Total n = 124 AHA n = 108 AHE n = 16 p value *
Sex at birth < 0.001
Female 32 22 (20.4%) % 10 (62.5 %)
Male 92 86 (79.6 %) 6 (37.5 %)
Region of residence 0.036
Central West 2 1 (0.9 %) 1 (6.3 %)
North 2 1 (0.9 %) 1 (6.3 %)
Northeast 2 1 (0.9 %) 1 (6.3 %)
South 45 38 (35.2 %) 7 (43.8 %)
Southeast 73 67 (62.0 %) 6 (37.5 %)
Geographical characteristics of the place of residence 0.016
Rural area 2 0 (0.0 %) 2 (12.5 %)
Urban area 122 108 (100.0 %) 14 (87.5 %)
Sexual orientation 0.004
Bisexual 8 8 (8.3 %) 0 (0.0 %)
Heterosexual 72 56 (58.3 %) 16 (100.0 %)
Homosexual 32 32 (33.3 %) 0 (0.0 %)
Gender identity 0.017
Cis man 81 75 (75.8 %) 6 (40.0 %)
Cis woman 31 22 (22.2 %) 9 (60.0 %)
Trans woman 1 1 (1.0 %) 0 (0.0 %)
Nonbinary 1 1 (1.0 %) 0 (0.0 %)
Inclusion Criteria < 0.001
Anicteric asymptomatic 4 4 (3.7%) 0 (0.0 %)
Anicteric symptomatic 20 11 (10.2 %) 9 (56.2 %)
Icteric symptomatic 100 93 (86.1 %) 7 (43.8 %)
Jaundice p < 0.001
No 24 15 (13.9 %) 9 (56.3 %)
Yes 100 93 (86.1 %) 7 (43.8 %)
Choluria 0.019
No 25 18 (16.7 %) 7 (43.8 %)
Yes 99 90 (83.3 %) 9 (56.3 %)
Surgery 0.005
No 92 85 (78.7 %) 7 (43.8 %)
Yes 32 23 (21.3 %) 9 (56.3 %)
Men who have sex with men (MSM) 0.003
MSM 38 38 (35.2 %) 0 (0.0 %)
Non MSM 86 70 (64.8 %) 16 (100.0 %)
Toxoplasmosis Anti-IgG < 0.001
Indeterminate 1 1 (0.9 %) 0 (0.0 %)
Non-reactive 87 82 (75.9 %) 5 (31.3 %)
Reactive 36 25 (23.1 %) 11 (68.8 %)

Note: Bold values are statistically significant. *p value corresponding to comparisons between patients with AHA and AHE

Demographic, clinical and laboratorial data of the HEV RNA positive case

The patient was a 32-year-old cisgender man residing in an urban area in Rondônia State, North Brazil. He identified as heterosexual, did not belong to the MSM group, and reported two sexual partners during the previous six months. He had a history of prior surgery (type not specified). The plasma sample was collected 19 days after symptom onset. At enrollment, he reported nausea, fever, and anorexia, without choluria or clinical jaundice, and was classified as anicteric. He reported no seafood consumption. The patient denied recent domestic or international travel.

Biochemical liver tests showed elevated aminotransferases and gamma-glutamyl transferase: AST 224 U/L, ALT 259 U/L, and GGT 259 U/L. Alkaline phosphatase was 99 U/L. Total and fractionated bilirubin levels were normal (total, 0.6 mg/dL; direct, 0.2 mg/dL; indirect, 0.4 mg/dL), consistent with the absence of jaundice. Total IgG was not available.

Laboratory evaluation demonstrated reactive anti-HEV IgM and detectable HEV RNA in plasma by qualitative RT-qPCR (Ct 38.1). Attempts to amplify the target regions for sequencing and genotyping were unsuccessful. HBsAg, total anti-HBc, and anti-HCV were non-reactive. Anti-HIV serology was reactive, with an HIV RNA level >5,400,000 IU/mL; molecular characterization identified HIV-1 group M, subtype B. Anti-HAV IgG was reactive, and HAV RNA was not detected, consistent with previous HAV exposure. Leptospira serology was non-reactive, and toxoplasmosis serology was reactive. Autoimmune testing showed antinuclear antibody reactivity with a fine-speckled nuclear pattern at a titer of 1:80 and a speckled cytoplasmic pattern at 1:80. Nucleolar and mitotic-apparatus patterns were non-reactive. Anti-LKM and ASMA-2 patterns involving the muscularis mucosa, glomerular mesangium, vascular smooth-muscle sheath, and intercellular tubular fibrils were non-reactive. Anti-actin IgG was 38.6 U; however, total IgG was unavailable, and these findings were reported descriptively without establishing autoimmune hepatitis. The concomitant HIV infection may have contributed to nonspecific autoantibody reactivity through immune dysregulation but not to the detection of HEV RNA by RT-qPCR.

Anti-HAV and Anti-HEV IgG cases

Anti-HAV IgG reactivity was detected in 1,352 participants (78.6%). Evidence of previous HEV exposure, defined by anti-HEV IgG reactivity, was identified in 89 participants (5.2%).

Table 2 presents the demographic, clinical, and behavioral characteristics associated with anti-HEV IgG reactivity; only statistically significant associations are shown, whereas non-significant results are provided in S2 Table. Anti-HEV IgG was more frequent among residents of the South, Southeast, and Central West regions and increased with age, from 1.0%–1.7% among individuals aged 18–34 years to 13.0% among those aged ≥65 years. Other associated factors included heterosexual orientation, absence of AHA, previous leptospirosis, reactive anti-HAV IgG, reactive total anti-HBc, and reactive anti-Toxoplasma gondii IgG. Anti-HEV IgG seropositivity was lower among MSM than among non-MSM individuals (1.4% versus 5.7%).

Table 2. Demographic, clinical, and behavioral characteristics associated with anti-HEV IgG reactivity.

n = 1720 IgG (−) n = 1631 IgG (+) n = 89 p valuea
Region of residence 0.007
Central West 125 118 (94.4 %) 7 (5.6 %)
North 244 239 (98.0 %) 5 (2.0 %)
Northeast 212 207 (97.6 %) 5 (2.4 %)
South 385 356 (92.5 %) 29 (7.5 %)
Southeast 754 711 (94.3 %) 43 (5.7 %)
Age group < 0.001
18-24 181 178 (98.3 %) 3 (1.7 %)
25-29 207 205 (99.0 %) 2 (1.0 %)
30-34 210 207 (98.6 %) 3 (1.4 %)
35-39 209 200 (95.7 %) 9 (4.3 %)
40-44 212 193 (91.0 %) 19 (9.0 %)
45-49 163 154 (94.5 %) 9 (5.5 %)
50-54 152 143 (94.1 %) 9 (5.9 %)
55-59 119 111 (93.3 %) 8 (6.7 %)
60-64 106 100 (94.3 %) 6 (5.7 %)
65+ 161 140 (87.0 %) 21 (13.0 %)
Sexual orientation 0.008
Bisexual 26 26 (100.0 %) 0 (0.0 %)
Heterosexual 1396 1316 (94.3 %) 80 (5.7 %)
Homosexual 215 212 (98.6 %) 3 (1.4 %)
AHA 0.040
Absent 1612 1524 (94.5 %) 88 (5.5 %)
Present 108 107 (99.1 %) 1 (0.9 %)
Leptospirosis 0.002
Non-reactive 1701 1617 (95.1 %) 84 (4.9 %)
Reactive 19 14 (73.7 %) 5 (26.3 %)
Seafood 0.002
No 1351 1270 (94.0 %) 81 (6.0 %)
Yes 367 359 (97.8 %) 8 (2.2 %)
Anti HAV IgG < 0.001
Non-reactive 368 365 (99.2 %) 3 (0.8 %)
Reactive 1349 1263 (93.6 %) 86 (6.4 %)
Anti-HBc Total 0.012
Non-reactive 1395 1332 (95.5 %) 63 (4.5 %)
Reactive 321 295 (91.9 %) 26 (8.1 %)
IgG Anti-Toxoplasmosis 0.0003
Non-reactive 787 763 (96.9 %) 24 (3.1 %)
Reactive 924 860 (93.1 %) 64 (6.9 %)
MSM 0.005
MSM 218 215 (98.6 %) 3 (1.4 %)
Non MSM 1502 1416 (94.3 %) 86 (5.7 %)

Note: Bold values are statistically significant. *p value corresponding to comparisons between anti-HEV IgG (-) and anti-HEV IgG (+) patients

Table 3 presents the logistic regression analysis of factors associated with anti-HEV IgG seropositivity. Individuals from the North (OR: 0.19; 95% CI: 0.06–0.49; p = 0.001) and Northeast (OR: 0.20; 95% CI: 0.06–0.53; p = 0.003) regions had lower odds of anti-HEV IgG seropositivity than those from the South, Southeast, and Central West regions. No age group showed a statistically significant association in the multivariable model, although individuals aged 40–44 years showed a trend toward higher odds compared with those aged 18–24 years (OR: 3.07; 95% CI: 0.96–13.7; p = 0.087). Non-heterosexual orientation showed a trend toward lower odds of anti-HEV IgG seropositivity (OR: 0.31; 95% CI: 0.07–0.90; p = 0.060), although this association did not reach statistical significance. Reactive anti-HAV IgG was strongly associated with increased odds of anti-HEV IgG seropositivity (OR: 5.77; 95% CI: 2.00–24.5; p = 0.005).

Table 3. Logistic regression analysis for factors associated with anti‐HEV IgG seropositivity.

ORa 95% CIa p value
Region of residence
Central West 0.73 0.28–1.69 0.5
North 0.19 0.06–0.49 0.001
Northeast 0.20 0.06–0.53 0.003
South — —
Southeast 0.75 0.44–1.28 0.3
Age group
18-24 — —
25-29 0.48 0.06–3.02 0.4
30-34 0.44 0.06–2.73 0.4
35-39 1.59 0.44–7.50 0.5
40-44 3.07 0.96–13.7 0.087
45-49 1.07 0.28–5.21 >0.9
50-54 1.35 0.36–6.47 0.7
55-59 1.30 0.34–6.41 0.7
60-64 1.12 0.27–5.65 0.9
65+ 2.50 0.77–11.4 0.2
Sexual orientation
Heterosexual — —
No Heterosexual 0.31 0.07–0.90 0.060
AHA
Non-reactive — —
Reactive 0.23 0.01–1.14 0.2
Leptospirose
Non-reactive — —
Reactive 3.00 0.63–10.8 0.12
Seafood
No — —
Yes 0.52 0.21–1.11 0.12
IgG Anti HAV
Non-reactive — —
Reactive 5.77 2.00–24.5 0.005

Note: Bold values are statistically significant.

a CI  =  confidence interval, OR  =  odds ratio.

Anti-HEV IgG seroprevalence varied across age groups and increased progressively with age (Fig 1). Frequencies were low among younger participants aged 18–34 years, ranging from 1.0% to 1.7%. Seroprevalence rose to 4.3% at ages 35–39 years and 9.0% at ages 40–44 years. It then fluctuated between 5.5% and 6.7% from ages 45–64 years. The highest prevalence was observed among participants aged ≥65 years (13.0%), supporting a positive association between older age and previous HEV exposure.

Fig 1. Anti‐HEV IgG seroprevalence by age group.

Fig 1

The final figure in the Results section summarizes the regional distribution of AHE cases and anti-HEV IgG seropositivity across Brazil (Fig 2).

Fig 2. Regional distribution of acute hepatitis E cases and anti-HEV IgG seropositivity in Brazil.

Fig 2

(A) Percentage distribution of the 16 acute hepatitis E (AHE) cases across the five Brazilian macro-regions. (B) Anti-HEV IgG seroprevalence within each Brazilian macro-region among the study participants.

The percentages in panel A represent the regional distribution of AHE cases, whereas those in panel B represent the proportion of participants who were anti-HEV IgG positive within each region. Fig 2 is original and was authored by the manuscript's authors. The map was generated in R from regional boundary shapefiles obtained through the geobr R package (version 2.0.0), which provides official geographic data from the Brazilian Institute of Geography and Statistics (IBGE: https://www.ibge.gov.br/en/home-eng.html?lang=en-GB).

Discussion

A multicenter, prospective, observational study was conducted between October 2019 and May 2023, including 1,721 patients (≥18 years) with suspected acute hepatitis from 31 referral centers across 16 Brazilian states. This study included referral centers from all five Brazilian macro-regions. Brazil is continental country; its extension is 48% of the land area and 50% of the population of South America. Brazil exhibits substantial demographic, geographic, socioeconomic, environmental, and healthcare-access heterogeneity across its five macroregions (North, Northeast, Central-West, Southeast, and South), which may influence the epidemiology of HAV and HEV infections. These regions differ markedly in population density, urbanization patterns, sanitation coverage, water supply infrastructure, income levels, livestock production systems, environmental conditions, and access to healthcare services. The North and Northeast regions generally present lower sanitation coverage and greater social vulnerability, whereas the South and Southeast are characterized by higher urbanization, better healthcare access, and more intensive swine production, a recognized reservoir of zoonotic HEV genotype 3. Such regional disparities may affect both the risk of exposure to HEV through environmental and zoonotic transmission routes and the likelihood of detection and diagnosis.

Importantly, the present study included only individuals aged 18 years or older. This characteristic may explain the higher frequency of HAV and HEV cases observed in the South and Southeast regions. In areas with better sanitation and lower exposure to enteric pathogens during childhood, a larger proportion of the population may remain susceptible into adulthood, resulting in a higher likelihood of infection being detected among adults. Conversely, in regions with poorer sanitation, exposure may occur earlier in life, leading to a lower proportion of susceptible adults. Therefore, regional differences in hepatitis occurrence may reflect not only variations in viral circulation but also disparities in sanitation, age-related exposure patterns, and healthcare access.

A total of 124 acute infections were identified; 12.9% were identified as AHE and 87.1% as AHA. A review on acute viral hepatitis around the world based on the Global Burden of Disease study 2021 estimated the following number of cases: AHA (160.86 million) and AHE (19.37 million). Projections suggest that by 2030, the global number of AHA cases could decrease to 152.9 million while the global number of AHE cases will rise to 20.5 million [35]. The AHA/AHE proportion we found in Brazil was 6.77 while in the world in 2021 it was 8.30. Other studies addressing AHE should be carried out in our country to further confirm the data shown herein and to better understand the burden of this infection in Brazil. The limited detection of HEV RNA among patients classified as AHE may partly reflect the interval between symptom onset and sample collection (median, 12.5 days; mean, 15.7 days), given the relatively short duration of viremia in acute HEV infection. By the time blood was collected, circulating viral RNA may already have declined below the assay detection limit in some patients. Future studies should consider collecting stool specimens in addition to blood, because fecal HEV RNA excretion may persist longer and may extend the window for molecular detection.

In our nationwide study using both serologic and molecular methods, anti‑HAV IgG was detected in 1,352 individuals (78.5%) vs. anti-‑HEV IgG in 89 (5.17%). This large gap likely reflects true epidemiologic differences: HAV is widespread in Brazil with high cumulative immunity from past infection and vaccination, while HEV transmission appears more focal, less common, and underrecognized due to limited surveillance and variable diagnostic availability. These findings support strengthening HEV testing and targeted epidemiologic studies.

Individuals from the North and Northeast exhibited significantly lower odds of anti-HEV IgG seropositivity compared to those from the South, Southeast and Central West regions. Previous data showed considerable heterogeneity across the regions and within distinct populations in the same geographic area. For example, prior studies in the North region reported varied seroprevalence rates: 4.5% in urban and 12.9%in rural areas [36]. The South region consistently reported the highest seroprevalence rates, often exceeding 10%, with some studies reaching up to 65% [37]. In contrast, studies in the Southeast, although variable, typically give results around 11% [38].

To address the geographic context of the sampled population, it is important to emphasize that the study included referral centers distributed across all five Brazilian macro-regions, encompassing heterogeneous demographic, socioeconomic, and environmental settings. These differences may help explain the regional variation observed in HEV exposure. The higher anti-HEV IgG seroprevalence in the South, Southeast, and Central West may reflect distinct patterns of urbanization, food consumption, animal exposure, livestock production, and access to diagnostic services, whereas the lower frequency observed in the North and Northeast may be influenced by differences in the sampled populations, healthcare-seeking patterns, and local transmission dynamics. In addition, the occurrence of AHE cases in both urban and rural settings suggests that HEV exposure in Brazil is not restricted to a single epidemiological scenario and may involve multiple routes of transmission, including environmental and zoonotic pathways. However, because the study was conducted in referral healthcare services and not as a population-based survey, regional comparisons should be interpreted with caution.

Our findings align with prior evidence showing substantial regional heterogeneity in HEV circulation in Brazil, with higher seroprevalence in the South, Southeast, and Central West and markedly lower levels in the North and Northeast. This pattern mirrors the epidemiological landscape described in previous studies and reinforces that HEV transmission in Brazil is focal and unevenly distributed. By providing standardized, multicenter data, our study confirms these regional disparities and demonstrates that HEV accounts for a measurable proportion of enterically transmitted acute hepatitis, supporting the need for routine HEV testing in the diagnostic evaluation of acute hepatitis.

A progressive increase in anti-HEV IgG seroprevalence was noted with advancing age, peaking at 13.0% among individuals aged ≥65 years. Younger age groups (18–34 years) had low seroprevalence (1.0–1.7%), with an increase beginning from the 35–39 age group. Although logistic regression did not reveal statistically significant associations for all age categories, a trend toward increased odds of seropositivity was observed in the 40–44 age group (OR: 3.07, 95% CI: 0.96–13.7; p = 0.087), compared to the 18–24 age group. These findings align with previous data from Brazil and other countries, where HEV seroprevalence generally increases with age [4].

Notable demographic and clinical differences were identified between AHA and AHE infections. Patients with AHE had a higher mean age (49.4 years) compared to those with AHA (34.9 years; p = 0.004). AHA was significantly associated with male sex (79.6%), whereas AHE was more prevalent among females (62.5%). AHA was also associated with bisexual (8.3%) and homosexual (33.3%) orientation, while all AHE cases occurred in individuals identifying as heterosexual (100%). These results support the established link between HAV and outbreaks among MSM, especially in high-income settings [30]. Indeed, this study confirmed a significant association between AHA and MSM (35.2% of HAV cases), whereas no AHE was reported in this group. More studies should be carried out and despite conflicting data, for the moment, MSM with unexplained jaundice, transaminitis, renal disease or neurological disease should be tested for HEV [39].

All AHA cases occurred in urban areas (100.0%), whereas AHE cases were reported in both urban and rural settings (12.5% rural). Clinically, AHA was associated with icteric symptomatic presentation (86.1%), with smaller proportions of anicteric symptomatic (10.2%) and anicteric asymptomatic cases (3.7%). In contrast, all AHE cases were symptomatic, with 56.3% presenting without jaundice and 43.8% with jaundice. These findings differ from existing literature, which typically reports jaundice in 5%–30% of HEV cases [40]. Although jaundice and choluria were less frequent in AHE vs. AHA (43.8% vs. 86.1% and 56.3% vs. 83.3%, respectively), the clinical presentations were similar, reinforcing the diagnostic challenges and the need to detect specific etiological markers for an accurate diagnosis. Anti-HEV IgM positivity has been detected in asymptomatic individuals in some previous population-based studies supporting the notion of subclinical circulation of the virus and highlighting the potential underestimation of true HEV seroprevalence [37,41]. It is noteworthy that in this study all patients that were diagnosed as AHE were symptomatic.

The markedly higher aminotransferase levels in the AHA group (ALT 1,150 U/L; AST 599 U/L) compared with the AHE group (ALT 233 U/L; AST 113 U/L) are in keeping with the typical biochemical profile of AHA, which often causes abrupt and pronounced hepatocellular injury with very large transaminase elevations. This difference likely reflects distinct pathophysiological and clinical patterns: HAV usually produces a sudden, symptomatic hepatic illness with high peak ALT and AST, whereas HEV—particularly sporadic HEV‑3 infections in older adults—tends to show more variable enzyme responses and a wider clinical spectrum that can include subclinical or milder biochemical abnormalities [42]. Differences in timing of sampling relative to symptom onset, as well as case characteristics such as age, comorbidities, and immune status, may further influence the observed group disparities.

The higher ALT/AST ratio observed in the AHA group indicates a disproportionately greater ALT rise relative to AST, consistent with a predominantly hepatocellular pattern of injury in acute HAV infection. The concurrent elevations in total and direct bilirubin suggest more pronounced impairment of bilirubin conjugation and/or excretion in HAV cases, producing more evident cholestasis and clinical jaundice than seen in the HEV group [43].

We found a significant association between acute HEV infection and anti-Toxoplasma IgG positivity (68.8% of HEV cases), which may reflect a common route of exposure, particularly ingestion of raw or undercooked meat. Previous studies reported an association between HEV and Toxoplasma markers in meat juice samples from pigs [44,45], but further research is needed to confirm this relationship in humans—particularly in Brazil after the large toxoplasmosis outbreak in Santa Maria, Rio Grande do Sul [46].

Interestingly, reactive anti-HEV IgG was strongly associated with reactive anti-HAV IgG, anti-HBc, and leptospirosis, indicating prior immunity or past exposure to hepatitis A and B, respectively, together with a superimposed leptospiral infection occurring alongside HEV; this pattern supports ongoing, overlapping zoonotic or environmental exposures in patients with a concurrent risk for previous hepatitis A or B infections [47,48].

Importantly, we did not assess HAV vaccination status, which limits the epidemiological interpretation of anti-HAV IgG positivity. Anti-HAV IgG indicates immunity but does not distinguish between vaccine-induced immunity and previous natural infection, whereas anti-HAV IgM is indicative of acute or recent infection [49]. Several experimental or research-based approaches have been proposed to address this limitation, including IgG avidity assays and antibody responses against non-structural HAV proteins [50–52]. However, these methods have important constraints, such as transient responses, limited diagnostic performance, and lack of routine clinical availability. Thus, in most clinical and epidemiological settings, accurate discrimination between vaccination and natural infection relies primarily on documented vaccination history rather than laboratory markers.

A recent scoping review of viral hepatitis in Brazil highlighted the substantial heterogeneity of HEV seroprevalence estimates reported across the country, with values ranging from 0.9% to 59.4% depending on the region and population studied. The review also demonstrated that most available evidence originates from regional studies conducted in selected populations, including blood donors, transplant recipients, people who use drugs, rural communities, and individuals with chronic liver disease, limiting the direct comparability of findings across settings. Furthermore, differences in study design, population characteristics, sampling strategies, geographic coverage, and laboratory methodologies may all contribute to the variability observed in the literature. In relation to acute hepatitis E, the review noted that confirmed cases remain uncommon and are likely underdetected, with most reports describing sporadic acute infections identified incidentally during investigations of unexplained hepatitis [53].

In line with these observations, the interpretation of HEV seroprevalence estimates should be approached with caution, as reported differences may reflect not only true epidemiological variation but also methodological heterogeneity among studies [54–56]. In addition, changes in anti-HEV serological assays over time may further influence comparisons between studies. In the present study, the use of a single standardized serological assay and harmonized procedures across all participating centers enhanced the internal consistency of the analyses and allowed direct comparisons among regions and population groups, providing robust nationwide data on HEV epidemiology in Brazil.

Conclusions

These findings should be interpreted in light of some limitations, including the referral-center-based design, which may not fully represent the general Brazilian population; the relatively small number of confirmed AHE cases, which limited subgroup analyses and reduced the statistical power to explore associations with specific environmental and dietary exposures collected in the questionnaire; the absence of complete information on HAV vaccination status; and the possibility that HEV RNA detection was affected by the short viremic window and timing of sample collection. On the other hand, the strength of this paper is that it provides more comparable seroprevalence estimates across different regions, as the same assay was consistently used for all analyzed samples.

The findings confirm significant regional and demographic differences in HEV seroprevalence, with higher rates in the South and Southeast, and a progressive increase with advancing age. Importantly, HEV accounted for 12.9% of enterically transmitted acute viral hepatitis cases, reinforcing its relevance as a public health concern. The observed epidemiological contrasts between HAV and HEV, in terms of age, sex, sexual orientation, and urban/rural distribution, underscore distinct transmission dynamics that require differentiated prevention strategies. Nevertheless, the frequent occurrence of common hepatitis symptoms among HEV cases emphasizes the need for routine inclusion of HEV testing in the diagnostic evaluation of acute hepatitis of unknown etiology. Collectively, these results call for greater awareness, improved surveillance, and the development of targeted public health policies aimed at reducing the burden of both HAV and HEV in Brazil.

Supporting information

S1 Table. Demographic, clinical, and behavioral characteristics of patients with acute hepatitis A (AHA) and acute hepatitis E (AHE).

(DOCX)

pntd.0014834.s001.docx (23.6KB, docx)
S2 Table. Demographic, clinical, and behavioral characteristics associated with anti-HEV IgG reactivity.

(DOCX)

pntd.0014834.s002.docx (34.9KB, docx)

Acknowledgments

The authors are grateful for the collaborative effort that involved several centers and their respective collaborators throughout Brazil. Each region of the country contributes its experience and resources to carry out this important study. The following list will show other collaborators who are essential for the success of this project. North Region: Neurisvania Soares—Centro de Medicina Tropical de Rondônia-RO; Ernandes Borges—Fundação de Medicina Tropical Dr. Vieira Machado de Manaus–AM; Belkis CB Hernandez, Juan CM Garcia—Unidade de Saúde de Referência de Doença de Rio Branco-AC. Northeast Region: Joilma SP Tobias, Renata M Assis, Eulália C Costa, Glauciene M Barros, Maria José Costa—Centro de Pesquisa Clínica Hospital Universitário do Maranhão–MA; Melissa MP Nascimento, Vanessa S Brito, Mariana S Assis, Beatriz V Russo, Ítalo JM Cavalcante, Sarah D Rocha—Hospital São José de Fortaleza–CE; Sidelcina R Pacheco—Hospital Universitário Professor Edgar Santos de Salvador–BA; Izolda M Moura - Hospital de Clínicas, Universidade Federal de Pernambuco (UFPE)—PE. South Region: Rochelle da Silva—Hospital Nereu Ramos de Florianópolis-SC; Aline Hansen—Hospital Municipal São José de Joinville-SC; Eridiane Lanzarine—Consórcio Intermunicipal de Saúde de Pato Branco-PR; Thaise S Deponti—Santa Casa de Porto Alegre—RS; Gabriele HW Silva—Centro de Testagem e Aconselhamento Santa Marta de Porto Alegre—RS; Gabriel TS Guerreiro, Marisa Boff Costa, Matheus T Michalczuk—Hospital de Clínicas de Porto Alegre–RS. Southeast Region: Carolina Dias—Hospital Felício Rocho de Belo Horizonte-MG; Paulo SF Sousa—Fundação Oswaldo Cruz do Rio de Janeiro–RJ; Patrícia P Martins, Rejane M Bernardo—Polo de Hepatites do IASERJ do Rio de Janeiro-RJ; Jorge Torresi, Daniela C Anastácio, Monize N Santana, Murilo B Crivillari, Gustavo AR Schneider—Instituto de Infectologia Emílio Ribas–SP; Daniel Added Filho, Thiago C Matos—Hospital Universitário de São Paulo-SP; Rosangela A Miranda, Lays Costa—Universidade Federal de São Paulo-SP; José R Piedade—Centro de Referência e Tratamento de DST AIDS de São Paulo-SP; Erika Y Ishigaki, Carlos H Miyashira, Renato M Prada, Ana Carla CM Silva—Faculdade de Medicina do ABC de São Paulo-SP; Ingrid SM Segal—Universidade Federal do Espírito Santo-ES. Center West region: Ivair M Souza—Hospital Dia Esterina Corsini de Campo Grande-MS; Weidilene M Assunção, Wagner I Brito—Hospital Universitário Júlio Muller Ambulatório 3 de Infectologia de Cuiabá-MT.

Data Availability

The dataset supporting the findings of this study has been deposited in the Open Science Framework (OSF) repository (https://osf.io/7gjsc).”.

Funding Statement

This study was supported by Hospital Israelita Albert Einstein through the Program for Supporting the Institutional Development of the Public Health System (PROADI‐SUS), supported by the Ministry of Health of Brazil (NUP:25000.171379/2023-67). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. KGO is a graduate student in the Graduate Program in Gastroenterology Sciences at Faculdade de Medicine, Universidade de São Paulo, NUSP 7069372 JRRP receives a fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) - Bolsista de produtividade, 306878/2023-2.

References

  • 1.Khuroo MS. Discovery of Hepatitis E and Its Impact on Global Health: A Journey of 44 Years about an Incredible Human-Interest Story. Viruses. 2023;15(8):1745. doi: 10.3390/v15081745 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Purdy MA, Drexler JF, Meng XJ, Norder H, Okamoto H, Van der Poel WHM. ICTV Virus Taxonomy Profile: Hepeviridae 2022. J Gen Virol. 2022;103(9). doi: 10.1099/jgv.0.001778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Alexandrova R, Tsachev I, Kirov P, Abudalleh A, Hristov H, Zhivkova T, et al. Hepatitis E Virus (HEV) Infection Among Immunocompromised Individuals: A Brief Narrative Review. Infect Drug Resist. 2024;17:1021–40. doi: 10.2147/IDR.S449221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int. 2020;40(7):1516–28. doi: 10.1111/liv.14468 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Aslan AT, Balaban HY. Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26(37):5543–60. doi: 10.3748/wjg.v26.i37.5543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nelson KE, Labrique AB, Kmush BL. Epidemiology of Genotype 1 and 2 Hepatitis E Virus Infections. Cold Spring Harb Perspect Med. 2019;9(6):a031732. doi: 10.1101/cshperspect.a031732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lee GH, Tan BH, Teo EC, Lim SG, Dan YY, Wee A, et al. Chronic Infection With Camelid Hepatitis E Virus in a Liver Transplant Recipient Who Regularly Consumes Camel Meat and Milk. Gastroenterology. 2016;150(2):355–7.e3. doi: 10.1053/j.gastro.2015.10.048 [DOI] [PubMed] [Google Scholar]
  • 8.Woo PC, Lau SK, Teng JL, Cao KY, Wernery U, Schountz T, et al. New Hepatitis E Virus Genotype in Bactrian Camels, Xinjiang, China, 2013. Emerg Infect Dis. 2016;22(12):2219–21. doi: 10.3201/eid2212.160979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization WHO. Hepatitis A fact sheet. 2026. [cited 2026 June 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a
  • 10.European Centre for Disease Prevention and Control. Hepatitis A factsheet. [cited 2026 June 15]. Available from: https://www.ecdc.europa.eu/en/hepatitis-A/facts
  • 11.de Brito WI, Souto FJD. Universal hepatitis A vaccination in Brazil: analysis of vaccination coverage and incidence five years after program implementation. Rev Bras Epidemiol. 2020;23:e200073. doi: 10.1590/1980-549720200073 [DOI] [PubMed] [Google Scholar]
  • 12.Moura WÉA, Caetano KAA, Lima JORE, Campos LR, Silva GRCE, de Moraes JC, et al. Hepatitis A vaccination coverage survey in 24-month-old children living in Brazilian capitals, 2020. Epidemiol Serv Saude. 2024;33(spe2):e20231162. doi: 10.1590/S2237-96222024v33e20231162.en [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kamar N, Selves J, Mansuy J-M, Ouezzani L, Péron J-M, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811–7. doi: 10.1056/NEJMoa0706992 [DOI] [PubMed] [Google Scholar]
  • 14.Meng XJ, Purcell H, Halbur PG, Lehman JR, Webb DM, Tsareva TS, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(18):9860–5. doi: 10.1073/pnas.94.18.9860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086. doi: 10.1038/nrdp.2017.86 [DOI] [PubMed] [Google Scholar]
  • 16.le Coutre P, Meisel H, Hofmann J, Röcken C, Vuong GL, Neuburger S, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58(5):699–702. doi: 10.1136/gut.2008.165571 [DOI] [PubMed] [Google Scholar]
  • 17.Wu C, Wu X, Xia J. Hepatitis E virus infection during pregnancy. Virol J. 2020;17(1):73. doi: 10.1186/s12985-020-01343-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Damiris K, Aghaie Meybodi M, Niazi M, Pyrsopoulos N. Hepatitis E in immunocompromised individuals. World J Hepatol. 2022;14(3):482–94. doi: 10.4254/wjh.v14.i3.482 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wallace SJ, Swann R, Donnelly M, Kemp L, Guaci J, Murray A, et al. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study. Aliment Pharmacol Ther. 2020;51(10):974–86. doi: 10.1111/apt.15704 [DOI] [PubMed] [Google Scholar]
  • 20.Epidemiology of Hepatitis A and Hepatitis E in Brazil. [cited 2026 October 1]. Available from: https://webhosting.uantwerpen.be/vhpba/files/html/Meetings_and_publications/Presentations/BRAS81.pdf
  • 21.Mariz CA, de Araújo LRMG, Lopes EP. Hepatitis E Virus Infection in Brazil: A Scoping Review of Epidemiological Features. Pathogens. 2025;14(9):895. doi: 10.3390/pathogens14090895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Santos-Silva S, Gonçalves HMR, Van der Poel WHM, Nascimento MSJ, Mesquita JR. Rat Hepatitis E Virus (Rocahepevirus ratti): A Systematic Review. Foods of Its Presence in Water, Food-Related Matrices, and Potential Risks to Human Health. Foods. 2025;14(14):2533. doi: 10.3390/foods14142533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Santos-Silva S, Moraes DFSD, López-López P, Paupério J, Queirós J, Rivero-Juarez A, et al. Detection of hepatitis E virus genotype 3 in an Algerian mouse (Mus spretus) in Portugal. Vet Res Commun. 2024;48(3):1803–12. doi: 10.1007/s11259-024-10293-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Salgado CRS, Silva A do NE, Arruda IF, Millar PR, Amendoeira MRR, Leon LAA, et al. Serological Evidence of Hepatitis E Virus Infection in Brazilian Equines. Microorganisms. 2023;11(11):2743. doi: 10.3390/microorganisms11112743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bastos C, Eisen AKA, Demoliner M, Heldt FH, Filippi M, de Abreu Góes Pereira VM, et al. Hepatitis E virus genotype 3 in bovine livers slaughtered in the state of Rio Grande do Sul, Brazil. Braz J Microbiol. 2022;53(3):1115–20. doi: 10.1007/s42770-022-00741-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Cunha L, Luchs A, Azevedo LS, Silva VCM, Lemos MF, Costa AC, et al. Detection of Hepatitis E Virus Genotype 3 in Feces of Capybaras (Hydrochoeris hydrochaeris) in Brazil. Viruses. 2023;15(2):335. doi: 10.3390/v15020335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Moraes DFSD, Mesquita JR, Dutra V, Nascimento MSJ. Systematic Review of Hepatitis E Virus in Brazil: A One-Health Approach of the Human-Animal-Environment Triad. Animals (Basel). 2021;11(8):2290. doi: 10.3390/ani11082290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sanabria-Cabrera J, Sanjuán-Jiménez R, Clavijo E, Medina-Cáliz I, González-Jiménez A, García-Cortés M, et al. Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. Liver Int. 2021;41(7):1523–31. doi: 10.1111/liv.14713 [DOI] [PubMed] [Google Scholar]
  • 29.Sitnik R, Maluf MM, Oliveira KG, Siqueira RA, Ferreira CEDS, Mangueira CLP, et al. Study protocol: epidemiological and clinical characteristics of acute viral hepatitis in Brazilian health services. BMJ Open. 2021;11(7):e045852. doi: 10.1136/bmjopen-2020-045852 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.de Oliveira KG, Vasconcelos MPA, Ton JT, Uehara SNO, Sitnik R, Ornelas Pereira Salvador de Oliveira D, et al. A Comprehensive Molecular and Serological Investigation of Hepatitis A Virus Among Patients With Suspected Acute Hepatitis: A Brazilian Study. J Med Virol. 2025;97(6):e70449. doi: 10.1002/jmv.70449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Hepatitis E Virus Infection. J Hepatol. 2018;68(6):1256–71. doi: 10.1016/j.jhep.2018.03.005 [DOI] [PubMed] [Google Scholar]
  • 32.Brasil M da SaúdeS de V em SaúdeD de V Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Manual Técnico para o Diagnóstico das Hepatites Virais. Brasília: Ministério da Saúde. 2016. [Google Scholar]
  • 33.Wang Y, Ling R, Erker JC, Zhang H, Li H, Desai S, et al. A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J Gen Virol. 1999;80 (Pt 1):169–77. doi: 10.1099/0022-1317-80-1-169 [DOI] [PubMed] [Google Scholar]
  • 34.Huang FF, Haqshenas G, Guenette DK, Halbur PG, Schommer SK, Pierson FW, et al. Detection by reverse transcription-PCR and genetic characterization of field isolates of swine hepatitis E virus from pigs in different geographic regions of the United States. J Clin Microbiol. 2002;40(4):1326–32. doi: 10.1128/JCM.40.4.1326-1332.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zhang L, Wang T, Zhou S, Li S, Mo T, Wu S. Update on the global burden of acute viral hepatitis in 2021. Front Public Health. 2025;13:1580863. doi: 10.3389/fpubh.2025.1580863 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Vitral CL, da Silva-Nunes M, Pinto MA, de Oliveira JM, Gaspar AMC, Pereira RCC, et al. Hepatitis A and E seroprevalence and associated risk factors: a community-based cross-sectional survey in rural Amazonia. BMC Infect Dis. 2014;14:458. doi: 10.1186/1471-2334-14-458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Passos-Castilho AM, Reinaldo MR, de Sena A, Granato CFH. High prevalence of hepatitis E virus antibodies in Sao Paulo, Southeastern Brazil: analysis of a group of blood donors representative of the general population. Braz J Infect Dis. 2017;21(5):535–9. doi: 10.1016/j.bjid.2017.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ferreira AC, Gomes-Gouvêa MS, Lisboa-Neto G, Mendes-Correa MCJ, Picone CM, Salles NA, et al. Serological and molecular markers of hepatitis E virus infection in HIV-infected patients in Brazil. Arch Virol. 2018;163(1):43–9. doi: 10.1007/s00705-017-3562-3 [DOI] [PubMed] [Google Scholar]
  • 39.Fitzpatrick C, Doherty S, George S, Richardson D. Hepatitis E in men who have sex with men: a systematic review. Frontline Gastroenterol. 2024;15(6):523–9. doi: 10.1136/flgastro-2024-102797 [DOI] [Google Scholar]
  • 40.Lhomme S, Marion O, Abravanel F, Izopet J, Kamar N. Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. J Clin Med. 2020;9(2):331. doi: 10.3390/jcm9020331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Conte DD, Luna LKS, Passarini A, Alves VRG, Caldeira DB, Cruz JS, et al. Hepatitis E virus infection among patients with altered levels of alanine aminotransferase. Braz J Infect Dis. 2021;25(6):101655. doi: 10.1016/j.bjid.2021.101655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Khongviwatsathien S, Thaweerat W, Atthakitmongkol T, Chotiyaputta W, Tanwandee T. A Comparison of Clinical Manifestations and Outcomes between Acute Sporadic Hepatitis A and Hepatitis E Infections in Thailand. Viruses. 2023;15(9):1888. doi: 10.3390/v15091888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol. 2021;27(16):1691–715. doi: 10.3748/wjg.v27.i16.1691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kelbert L, Stephan R, Furtwaengler C, Pinillo JA, Morach M, Nüesch-Inderbinen M. Prevalence of Toxoplasma gondii, Hepatitis E Virus, and Salmonella Antibodies in Meat Juice Samples from Pigs at Slaughter in Switzerland. J Food Prot. 2021;84(10):1760–4. doi: 10.4315/JFP-21-183 [DOI] [PubMed] [Google Scholar]
  • 45.Dzierzon J, Oswaldi V, Merle R, Langkabel N, Meemken D. High Predictive Power of Meat Juice Serology on the Presence of Hepatitis E Virus in Slaughter Pigs. Foodborne Pathog Dis. 2020;17(11):687–92. doi: 10.1089/fpd.2020.2797 [DOI] [PubMed] [Google Scholar]
  • 46.Fernandes FD, Samoel GVA, Guerra RR, Bräunig P, Machado DWN, Cargnelutti JF, et al. Five years of the biggest outbreak of human toxoplasmosis in Santa Maria, Brazil: a review. Parasitol Res. 2023;123(1):76. doi: 10.1007/s00436-023-08073-1 [DOI] [PubMed] [Google Scholar]
  • 47.Haake DA, Levett PN. Leptospirosis in humans. Clin Microbiol Rev. 2015;28(3):1–26. doi: 10.1007/978-3-662-45059-8_5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wu JC, Chen CM, Chiang TY. Clinical relevance of hepatitis E virus infection in Taiwan: a cross-sectional study of patients with acute hepatitis. J Clin Microbiol. 2000;38(12):4181–5. [Google Scholar]
  • 49.Centers for Disease Control and Prevention CDC. Clinical Screening and Diagnosis for Hepatitis A. 2024. [cited 2026 June 15]. Available from: https://www.cdc.gov/hepatitis-a/hcp/diagnosis-testing/index.html
  • 50.Roque-Afonso A-M, Grangeot-Keros L, Roquebert B, Desbois D, Poveda J-D, Mackiewicz V, et al. Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus. J Clin Microbiol. 2004;42(11):5121–4. doi: 10.1128/JCM.42.11.5121-5124.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Desbois D, Grangeot-Keros L, Roquebert B, Roque-Afonso A-M, Mackiewicz V, Poveda J-D, et al. Usefulness of specific IgG avidity for diagnosis of hepatitis A infection. Gastroenterol Clin Biol. 2005;29(5):573–6. doi: 10.1016/s0399-8320(05)82132-3 [DOI] [PubMed] [Google Scholar]
  • 52.Hunderkar S, Ganorkar N, Walimbe A, Lole K. Evaluation of hepatitis A virus recombinant proteins for detecting anti-HAV IgM and IgG antibodies. Microbiol Spectr. 2025;13(4):e0152824. doi: 10.1128/spectrum.01528-24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Inoue CA, Domingues TSP, Sucupira MCA, Sitnik R, Panico CT, de Oliveira DOPS, et al. The epidemiology of the viral hepatitis in Brazil: A scoping review. PLoS One. 2026;21(7):e0353840. doi: 10.1371/journal.pone.0353840 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Avellon A, Morago L, Garcia-Galera del Carmen M, Munoz M, Echevarría J-M. Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. J Med Virol. 2015;87(11):1934–9. doi: 10.1002/jmv.24251 [DOI] [PubMed] [Google Scholar]
  • 55.Zhang Q, Zong X, Li D, Lin J, Li L. Performance Evaluation of Different Commercial Serological Kits for Diagnosis of Acute Hepatitis E Viral Infection. Pol J Microbiol. 2020;69(2):217–22. doi: 10.33073/pjm-2020-025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Capai L, Falchi A, Charrel R. Meta-Analysis of Human IgG anti-HEV Seroprevalence in Industrialized Countries and a Review of Literature. Viruses. 2019;11(1):84. doi: 10.3390/v11010084 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0014834.r001

Decision Letter 0

Anabella Clara Fantilli, Stephanie N Seifert

5 May 2026

Hepatitis E in Brazil: Investigation of Suspected Acute Hepatitis Cases

PLOS Neglected Tropical Diseases

Dear Dr. Pinho,

Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within by Jul 04 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Anabella Clara Fantilli

Guest Editor

PLOS Neglected Tropical Diseases

Stephanie Seifert

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Additional Editor Comments:

Overall, there are several important issues that need to be addressed before a final decision can be made. A major concern raised consistently by all reviewers relates to the need for greater clarity and consistency across the manuscript, particularly regarding the study objectives and their alignment with the Methods and Results sections. In its current form, there is some ambiguity about the role of HAV in the study (i.e., whether it is part of the main objective or primarily included for comparative purposes with HEV).

In addition, the Methods section requires further detail and clarification, most importantly regarding the criteria used for the diagnosis of acute hepatitis E, which is essential for the interpretation of the results.The Results section would benefit from the inclusion of currently missing or insufficiently reported data, and the Discussion and Conclusion requires further refinement to ensure that interpretations are fully supported by the results presented and that certain statements are appropriately qualified.

Beyond the reviewers’ suggestions, I would like to highlight a few additional points. First, the manuscript would benefit from a thorough revision of the English language, as there are several grammatical issues and redundancies throughout the text (e.g., repeated definitions of abbreviations such as HEV, AHA, AHE, MSM). Improving the overall readability will greatly strengthen the manuscript.

Second, regarding the previous seroprevalence data mentioned in the Introduction and Discussion, it is important to acknowledge that part of the heterogeneity observed across regions may be due to the use of different serological assays in previous studies, which complicates direct comparisons. This aspect should be explicitly considered when interpreting and discussing regional differences. In this context, a strength of the present study is that it provides more comparable seroprevalence estimates across different regions, as the same assay was consistently used for all analyzed samples.

Finally, please ensure that all requested revisions are carefully addressed, as well as any additional issues identified during your revision. A final decision will be made based on the revised version of the manuscript.

Journal Requirements:

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Ana Catharina de Seixas Santos Nastri, and Mario Peribañez Gonzalez. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions

2) We do not publish any copyright or trademark symbols that usually accompany proprietary names, eg ©,  ®, or TM  (e.g. next to drug or reagent names). Therefore please remove all instances of trademark/copyright symbols throughout the text, including:

- ® on page: 13.

3) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:

https://journals.plos.org/plosntds/s/figures

4) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

- State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM)."

- State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.".

If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d

Reviewers' Comments:

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: 1. Authors refer to a previous published work where samples were collected, however some specifications should be included in this manuscript as well; e.g. number of samples included, the inclusion criteria should be described in more detailed (hematological, biochemical parameters, tests for other hepatitis virus or associated viruses).

2. HAV vaccination should be more explicitly mentioned and treated as a variable in the study, also it would be important to describe and discuss the HAV vaccination program and coverage throughout Brazil.

3. Regarding the only RT-qPCR positive sample:

a. What was the Ct and RNA concentration obtained?

b. What epidemiological and socio-demographic characteristics presented this patient?

c. When authors mention that this sample could not be sequenced, which PCR method was employed? Was it due to low viral titer or lack of sensitivity of the test selected? Please clarify this point in the manuscript.

Ethical comitee approval should be explicitly included in this manuscript, not only cited the previous work where the samples were obtained.

Reviewer #2: The objectives of the study are relevant; however, there is an inconsistency between how they are presented in the Abstract and in the main manuscript. In particular, the relationship between the different analytical components described in the Methods and the stated objectives is not entirely clear, which may lead to some confusion regarding the scope of the study. The multicenter prospective design is appropriate to address the study, and the study population is clearly described and suitable, including adults with suspected acute hepatitis across multiple regions of Brazil. The overall sample size is large and adequate for the main analyses. The statistical methods used are appropriate and adequately described; however, more complete reporting of the variables analyzed, including those not found to be statistically significant (see specific comment), would improve transparency.

Reviewer #3: The title does not mention the detection of HAV. Please, modify it including HAV.

In the Abstract, it is mentioned that anti‑HEV IgG prevalence was higher among men who have sex with men (MSM), whereas in the text, it is stated that the association is with heterosexual persons. Please, clarify.

1-The introduction is too long. While the information provided is relevant to both the topic and the article, it is presented with an excessive level of detail which is irrelevant to the article's objective. For instance, the paragraph 2 of page 11, enumerates all reports of HEV infections with viral RNA detection, which is unnecessarily exhaustive for a paper’s introduction. A more concise approach—briefly acknowledging the existence of prior reports and summarizing key aspects such as detected genotypes/subtypes, studied populations, and types of biological samples—would be sufficient to contextualize the study. The same applies to the second paragraph on page 10 of the introduction, which mentions studies conducted between 1999 and 2011. Please revise this section accordingly, ensuring that both these paragraphs and the entire introduction are appropriately summarized.

2-Remove the following sentence (introduction, page 10), as rat HEV (Rocahepevirus ratti) is a different virus and this study focuses on HEV (Paslahepevirus balayani): “In bivalve mollusks sampled in Maranhão state, rat HEV RNA was detected in 2.2% of samples [17].”

3-Introduction, page 9, second paragraph, line 5: add the word “than” between “more” and “2 weeks”, so the sentence says “more than 2 weeks”.

4- Although the stated objective of the study is “to determine the prevalence of HEV infection through serological analysis of anti-HEV IgG and IgM antibodies, as well as molecular detection of viral RNA”, it appears that the actual aim is to determine whether HEV is a causative agent of acute infections in Brazil and at what frequency. Please clarify this point in the Introduction.

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: 4. I suggest authors to include a map of Brazil showing the distribution of the detected HEV cases for a more graphical visualization.

5. The Discussion section lacks information about the selected sampled regions, such as its different socio-demographic and geographic contexts or other relevant aspects that could help enrich the discussion as a possible association with HEV cases.

Reviewer #2: The analyses presented are generally consistent with the stated analysis plan, including both the comparison between acute hepatitis A and E cases and the evaluation of factors associated with anti-HEV IgG seropositivity. The results are clearly presented overall and follow a logical structure; however, in some instances, only statistically significant findings are reported. The tables are of adequate quality and generally clear.

Reviewer #3: 5-In the first paragraph of the results section (page 15), it is stated that “16 patients were classified as acute hepatitis E, all of them anti-HEV IgM (+) but just one with detectable HEV RNA by PCR”. Regarding this, what criteria were used for the diagnosis of acute hepatitis E, considering that there are discrepancies worldwide? For example, the European Association for the Study of the Liver (EASL) guidelines state that the diagnosis of acute hepatitis E is established by the presence of HEV-RNA with or without serological markers (specific IgM and/or IgG), or by the presence of IgM together with rising anti-HEV IgG levels. Haw was the specific IgG status in the IgM+ patients? The criterion used is crucial and must be clarified in the introduction or materials and methods sections.

6-Regarding the sentence (page 16, Results section) “Anti-HEV IgG antibodies, indicating previous exposure to hepatitis E virus, were present in 5.17% (n = 89) of the study population, while anti-HAV IgG antibodies were observed in a substantially higher proportion of participants (78.56%; n = 1,352)”: Were any of the anti-HEV IgG–positive samples from the same patients who also had detectable anti-HEV IgM? The same clarification applies to HAV. Please clarify this point, as in such cases these would not represent past infections, but rather the presence of an additional marker in the context of an acute infection, and the seroprevalence percentages could therefore vary.

7-Table 1: there is an extra parenthesis (first line). The p value shown, belongs to HAV or HEV? This is not clear in the tables, please clarify there.

8-It is noteworthy that antibodies against HEV (both IgM and IgG) are related to the presence of anti-Toxoplasma IgG. Could this be a cross-reactivity? What are the reactivity levels of the anti-HEV antibodies? This might provide a clue.

9-Only one sample tested positive for HEV RNA; how many days after symptom onset was this patient at the time of sampling? What about those who were HEV IgM-positive? What were the antibody reactivity indices for the detected cases? Cross-reactivity between HEV and Epstein-Barr virus or cytomegalovirus has been reported (see references below), could this be a possibility here? How were the serological markers for this virus?

References:

Fogeda et al. 2009. J Clin Virol. 45 (3): 259-261. https://doi.org/10.1016/j.jcv.2009.05.022

Hyams et al. 2013. Med Virol. https://doi.org/10.1002/jmv.23827

10-In the Discussion section, it is stated that “sequencing of the single HEV RNA–positive sample was not possible, precluding direct characterization of the circulating genotypes. Nonetheless, the predominantly milder clinical presentations observed, together with lower and short-lived viral loads, agree with findings from previous studies conducted in Brazil…”. However, although milder clinical symptoms and low viral loads are mentioned here, these data are not presented in the Results section. If these analyses were performed, please include these correlations in the Results section (i.e., clinical symptoms of patients with hepatitis E and the corresponding viral load measurements).

11-In the last paragraph of page 23, where it states “exhibited significantly lower odds of IgG seropositivity,” please specify “HEV IgG.”

12-In the Discussion section (pages 24 and 25), it is stated: “Indeed, there is no strong evidence that MSM have lower HEV frequency and there is some suggestion of possible sexual transmission in MSM, but there are also multiple studies with no association. Finally, we agree that more studies should be carried out and for the moment, despite conflicting data, hepatitis E may be sexually transmissible in MSM, and MSM with unexplained jaundice, increased transaminases, renal disease or neurological disease should be tested.” It is important to clarify at this point that HEV is not considered a sexually transmitted virus, similar to HAV. Rather, these viruses—particularly HAV, for which numerous reports exist worldwide—are associated with sexual practices involving fecal–oral exposure (e.g., hand–anus–mouth contact), rather than transmission through mucosal sexual contact. Therefore, referring to these cases as “sexual transmission” may be misleading. Please, remove this term and instead clarify this distinction.

13-In the Discussion (page 25), it is stated that “Clinically, AHA was associated with symptomatic presentations with jaundice (86.1%), as well as with asymptomatic or non-jaundiced symptomatic cases (9.3% and 4.6%, respectively). In contrast, all AHE cases were symptomatic, with 56.2% presenting without jaundice and 43.8% with jaundice”, also “Although jaundice and choluria were less frequent in AHE vs. AHA (43.8% vs. 86.1% and 56.3% vs. 83.3%), clinical pictures are similar…”, and “The markedly higher aminotransferase levels in the AHA group (ALT 1,150 U/L; AST 599 U/L) compared with the AHE group (ALT 233 U/L; AST 113 U/L) are in keeping with the typical biochemical profile of acute hepatitis A, which often causes abrupt and pronounced hepatocellular injury with very large transaminase elevations”. However, these data are not presented in the Results section (or briefly mentioned). Please include them there if they are to be discussed.

14-Regarding the sentence “Nevertheless, prior population-based studies in asymptomatic individuals have demonstrated anti-HEV IgM positivity [24,39], supporting the notion of subclinical circulation of the virus and highlighting the potential underestimation of true HEV seroprevalence” of the Discussion section (page 25), were any of the HEV IgM–positive samples obtained from asymptomatic individuals, or did they all correspond to symptomatic patients? This is an important point that should be reported in the Results section and potentially addressed in the Discussion.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The limitations of the study are not clearly presented in the conclusions

Reviewer #2: The conclusions are supported by the data presented and are consistent with the main findings of the study, particularly regarding regional differences, age-related trends, and the proportion of acute hepatitis attributable to HEV. The comparison between HAV and HEV is appropriately highlighted and contributes to the understanding of their distinct epidemiological patterns. The manuscript does effectively discuss the relevance of the findings in advancing the understanding of HEV epidemiology, and the public health implications are clearly stated, especially in terms of surveillance and diagnostic strategies.

Reviewer #3: 15-Conclusions: Before mentioning that “HEV accounted for 12.9% of enterically transmitted acute viral hepatitis cases”, the diagnostic criteria for acute hepatitis E should be reconsidered, taking into account international guidelines (such as those from the EASL previously mentioned or the European Centre for Disease Prevention and Control). There is also likely a diagnostic criterion (with its corresponding algorithm) from the Brazilian Ministry of Health, which should be referenced somewhere in the manuscript.

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: Minor specific comments:

Abstract:

A minor wording adjustment in the Abstract objective may help clarify the role of HAV as a reference group.

Please specify whether acute infections were identified by detection of RNA, IgM, or both.

Objective - page 12:

“Patients with suspected acute hepatitis were obtained from …” should be revised, as this wording is not standard for study populations. Consider using “… were enrolled” or “… were included.”

Results – page 16

Table 2 includes only statistically significant associations. It would be helpful to also provide information on the variables analyzed that were not significantly associated, either in the table or as supplementary material, to give a more complete overview of the analysis.

Discussion – page 27:

It may be helpful to briefly mention the hepatitis A vaccination program in Brazil, as this may have influenced the observed anti-HAV IgG seroprevalence and its comparison with HEV.

Reviewer #3: (No Response)

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The manuscript "Hepatitis E in Brazil: Investigation of Suspected Acute Hepatitis Cases" reports a multicenter study of hepatitis E in patients with acute hepatitis from Brazil, correlated to hepatitis A cases and socio-demographic factors, which could help expand the epidemiological knowledge of this disease in Brazil.

The manuscript is generally well-written, but some points in the methodology need to be further described.

Reviewer #2: This manuscript addresses a relevant and underrecognized topic and provides valuable data on HEV epidemiology in Brazil. Overall, the study is well conducted and the findings are of interest for both clinical and public health perspectives. A key point for improvement relates to the consistency and clarity of the study objectives across sections, which would benefit from better alignment with the analytical approach described in the Methods. Addressing this aspect, along with the additional comments outlined above, would strengthen the work.

Reviewer #3: This article provides valuable information on HEV and the acute infections it causes in the Brazilian population, covering broad regions of the country and analyzing a large number of samples. However, major revisions are required before it can be published (see comments for each section).

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0014834.r003

Decision Letter 1

Anabella Clara Fantilli, Stephanie N Seifert

5 Oct 2026

Clinical and Epidemiological Comparison of Hepatitis A and E Infections in Brazil

Response to ReviewersRevised Manuscript with Track ChangesManuscript'.

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Additional Editor Comments (if provided):

Journal Requirements:

1) Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150-200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines:

https://journals.plos.org/plosntds/s/submission-guidelines#loc-parts-of-a-submission

2) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

i) State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

ii) If any authors received a salary from any of your funders, please state which authors and which funders..

If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d

Reviewers' comments:

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: All previous comments were properly addressed

Reviewer #2: The study objectives are clearly articulated and are consistent with the analyses and results presented. The study design and population are appropriate to address the stated objectives, and the statistical analyses are appropriate and adequately support the conclusions. The sample size appears reasonable for the scope and design of the study. I have no concerns regarding ethical or regulatory requirements.

Reviewer #3: The introduction was significantly improved, presenting background information relevant to the paper's purpose and clearly outlining the objectives.

Materials and Methods: Although the case definition for acute hepatitis E has been clarified in accordance with international guidelines, the information presented does not exactly match what some of the guidelines state. In page 13 it is mentioned that acute hepatitis E is defined by the detection of anti-HEV IgM antibodies and/or HEV RNA, noting that all guidelines agree on this point. However, the EASL guideline defines "current acute infection" as the presence of HEV RNA—with or without anti-HEV IgM—but excludes cases where only anti-HEV IgM is present. On the other hand, WHO guidelines do accept the presence of anti-HEV IgM alone, in conjunction with symptoms of acute hepatitis, as a confirmatory diagnostic criterion for the infection. Therefore, the statement should be revised to accurately reflect these differences among the international guidelines.

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: All previous comments were properly addressed

Reviewer #2: The analyses presented are consistent with the stated objectives and analysis plan, and the results are generally clearly and adequately presented. The figures are of sufficient quality for interpretation, although Figure 2 requires revision to ensure consistency between the panel labels, figure legend, and corresponding descriptions.

Reviewer #3: The results are clearly presented. Some revision needed:

Please, remove the sentence “…indicating active infection with low-level viral replication” in page 19, since it is not possible to know the level of viral replication just by the Ct level, moreover in a plasma sample. Regarding this RNA-HEV positive case, did the patient have any history of travel? Additionally, did the patient have any evidence of autoimmune markers? In the reviewer’s response, authors mentioned that the sample was collected 19 days after symptoms onset; please, add this information to the Results section (to the paragraph with the case report). Including this information would add value to the case and all the Results.

The authors included a Figure (Fig2) in the Discussion section. It is important to note that the maps in this figure present data obtained during the study; therefore, they should be moved to the Results section. These data should then be discussed in the Discussion section, just as the differences observed among the various geographic regions of Brazil were discussed. Please, move the figure to the Results section. Added to this, in the legend of the Figure, there is a point “C” explanation, but there is no panel “C” in the Figure. Please, clarify.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: All previous comments were properly addressed

Reviewer #2: The conclusions are supported by the data presented and are consistent with the study objectives and findings. The limitations of the study are adequately described, and the Discussion addresses how the findings contribute to the understanding of hepatitis A and E infections in Brazil.

Reviewer #3: (No Response)

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: The remaining revisions are mainly editorial and concern clarity, consistency, and presentation of the manuscript. These include minor changes to the text, standardization of data presentation, and revision of a figure.

Reviewer #3: (No Response)

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: All previous comments were properly addressed and the manuscript has improved significantly

Reviewer #2: The manuscript has improved substantially compared with the previous version. The objectives are now clearer and better aligned with the analyses and results, the statistical analyses are more clearly presented, and the Discussion is better focused on the findings. The study addresses a relevant topic and provides useful information on hepatitis A and E infections in Brazil. The remaining comments are mainly related to clarity, consistency, and presentation, and I do not consider that additional experiments or substantial new analyses are required.

Reviewer #3: The manuscript has been substantially improved. The objective has been clarified, the different sections have been improved, and even the title has been modified so that it more accurately reflects the work carried out.

The introduction was significantly improved, presenting background information relevant to the paper's purpose and clearly outlining the objectives.

Some minor correction is still needed:

1-Introduction, page 7: when starting to speak of HAV, please, start in a different paragraph.

2-Materials and Methods: Although the case definition for acute hepatitis E has been clarified in accordance with international guidelines, the information presented does not exactly match what some of the guidelines state. In page 13 it is mentioned that acute hepatitis E is defined by the detection of anti-HEV IgM antibodies and/or HEV RNA, noting that all guidelines agree on this point. However, the EASL guideline defines "current acute infection" as the presence of HEV RNA—with or without anti-HEV IgM—but excludes cases where only anti-HEV IgM is present. On the other hand, WHO guidelines do accept the presence of anti-HEV IgM alone, in conjunction with symptoms of acute hepatitis, as a confirmatory diagnostic criterion for the infection. Therefore, the statement should be revised to accurately reflect these differences among the international guidelines.

3-Resultas Section: Please, remove the sentence “…indicating active infection with low-level viral replication” in page 19, since it is not possible to know the level of viral replication just by the Ct level, moreover in a plasma sample. Regarding this RNA-HEV positive case, did the patient have any history of travel? Additionally, did the patient have any evidence of autoimmune markers? In the reviewer’s response, authors mentioned that the sample was collected 19 days after symptoms onset; please, add this information to the Results section (to the paragraph with the case report). Including this information would add value to the case and all the Results.

4- The authors included a Figure (Fig2) in the Discussion section. It is important to note that the maps in this figure present data obtained during the study; therefore, they should be moved to the Results section. These data should then be discussed in the Discussion section, just as the differences observed among the various geographic regions of Brazil were discussed. Please, move the figure to the Results section. Added to this, in the legend of the Figure, there is a point “C” explanation, but there is no panel “C” in the Figure. Please, clarify.

5-Discussion section: please, add a sentence mentioning possible reasons for the failure to detect HEV-RNA in patients with acute HEV infection. One possible explanation could be the time elapsed between symptom onset and sample collection (averaging 12 days), given the short duration of viremia. This issue could be addressed by collecting stool samples, as the period of viral excretion is longer (this also could be mentioned).

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure resubmission:

Reproducibility: -->To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols-->?>

Attachment

Submitted filename: R1.docx

pntd.0014834.s004.docx (14KB, docx)
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0014834.r005

Decision Letter 2

Anabella Clara Fantilli, Stephanie N Seifert

19 Oct 2026

Dear Dr Pinho,

We are pleased to inform you that your manuscript 'Hepatitis E in Suspected Acute Hepatitis Cases in Brazil: A Comparison with Hepatitis A' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Anabella Clara Fantilli

Guest Editor

PLOS Neglected Tropical Diseases

Stephanie Seifert

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #2: I thank the authors for their careful revisions. The previous comments have been adequately addressed: the title now better reflects the focus on hepatitis E, the introduction has been improved with a clearer separation of the HEV and HAV descriptions, figure 2 has been moved to the results section with corrected panel labels and legend, and the discussion now addresses the possible reasons for the limited detection of HEV RNA.

Reviewer #3: All requested changes and suggestions were implemented; the article improved significantly.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0014834.r006

Acceptance letter

Anabella Clara Fantilli, Stephanie N Seifert

Dear Dr Pinho,

We are delighted to inform you that your manuscript, "Hepatitis E in Suspected Acute Hepatitis Cases in Brazil: A Comparison with Hepatitis A," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Demographic, clinical, and behavioral characteristics of patients with acute hepatitis A (AHA) and acute hepatitis E (AHE).

    (DOCX)

    pntd.0014834.s001.docx (23.6KB, docx)
    S2 Table. Demographic, clinical, and behavioral characteristics associated with anti-HEV IgG reactivity.

    (DOCX)

    pntd.0014834.s002.docx (34.9KB, docx)
    Attachment

    Submitted filename: Response Letter.docx

    pntd.0014834.s003.docx (38KB, docx)
    Attachment

    Submitted filename: R1.docx

    pntd.0014834.s004.docx (14KB, docx)
    Attachment

    Submitted filename: Response to Reviewers2.docx

    pntd.0014834.s005.docx (56.6KB, docx)

    Data Availability Statement

    The dataset supporting the findings of this study has been deposited in the Open Science Framework (OSF) repository (https://osf.io/7gjsc).”.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES